AstraZeneca’s $2 billion Summit stake wins backing from UBS and Jefferies Proactive uses images sourced from Shutterstock
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, has won positive responses from UBS and Jefferies after investing $2 billion in Summit Therapeutics and agreeing a cancer drug collaboration.
UBS said the investment gives AstraZeneca exposure to the programmed death-1 and vascular endothelial growth factor (PD-1/VEGF) class, which combines immune-system activation with inhibition of tumour blood vessel growth.
The broker said emerging evidence suggests the drug class could outperform existing PD-1 treatments in some cancers, making combination data increasingly important if it develops into a new standard of care.
AstraZeneca will initially test Summit’s ivonescimab with sonesitatug vedotin, an antibody drug conjugate (ADC) designed to deliver a cancer-killing treatment directly to tumour cells, in gastrointestinal cancers.
Jefferies described the transaction as “strategically smart”, saying it gives AstraZeneca a route to combine its oncology ADC portfolio with a PD-1/VEGF medicine without taking on the risk of a larger acquisition before key clinical results.
The broker said the agreement gives AstraZeneca development flexibility while ensuring it remains involved if the treatment approach is validated globally.
AstraZeneca will receive rights equivalent to about 12% of Summit’s outstanding common stock, or 10.6% on a fully diluted basis, while both companies will retain development and commercial rights to their respective medicines.
UBS said the implied investment price of $18.36 per Summit share represents an 18.6% premium to the company’s closing price on 28 September. uec96192
Attention will now turn to Summit’s HARMONi-3 Phase III trial in first-line metastatic non-small cell lung cancer (NSCLC), with Jefferies expecting the first major readout in the fourth quarter of 2026.
Jefferies maintained a Buy rating on AstraZeneca with a 17,500p price target, while UBS also retained a Buy recommendation with a 15,200p target.
UBS said AstraZeneca’s investment was based on publicly available information, with Summit confirming the drugmaker had not received access to undisclosed HARMONi-3 results.